Hosted on MSN1d
Aclaris Therapeutics Unveils Promising Data on ATI-2138, a Novel Dual ITK/JAK3 InhibitorAclaris Therapeutics, Inc. (NASDAQ: ACRS) has announced significant findings about ATI-2138, a novel investigational drug ...
AceLink is advancing a small-molecule treatment option for Fabry disease, which could provide a more convenient alternative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback